The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...

The introduction of anti-VEGF agents has revolutionized the field of medical retina care by reducing rates of vision loss and ...

Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...

Compared with sham, patients implanted with NT-501 (revakinagene taroretcel, Neurotech Pharmaceuticals) for macular telangiectasia (MacTel) experienced less ellipsoid zone loss, a reduction in the ...

001). PDUFA date: March 18, 2025. Macular telangiectasia type 2 (MacTel) is a rare, progressive eye disease that affects the macula and causes a gradual deterioration in central vision.

In 2022, more than 941,600 Americans died from cardiovascular disease. Heart disease remains the leading cause of death in the United States, according to a new report. The American Heart ...